Embattled TAVR Device Myval Meets Expectations in Trial, but Trouble Still Ahead

(MedPage Today) — For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed well enough in the COMPARE-TAVI 1 randomized trial, but its rates of pacemakers and paravalvular leaks…

Source link : https://www.medpagetoday.com/cardiology/pci/114984

Author :

Publish date : 2025-04-04 21:44:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Embattled TAVR Device Myval Meets Expectations in Trial, but Trouble Still Ahead

Switch to Tirzepatide in T2D More Effective Than Upping Dulaglutide Dose

How a home DNA test finally revealed the truth

Related Posts

Crash Risk After Heart Device Implant Still Hard to Predict

Without Federal Student Loans, I Wouldn’t Have My MD

FDA Approves First Treatment for MAS in Still Disease

Does Medicaid Reimbursement for Postpartum Depression Screening Catch More Cases?

Experts Skeptical of Trump’s So-Called ‘Gold Standard Science’

Single antiviral shot could offer better protection than flu vaccines

Crash Risk After Heart Device Implant Still Hard to Predict

Without Federal Student Loans, I Wouldn’t Have My MD

FDA Approves First Treatment for MAS in Still Disease

Does Medicaid Reimbursement for Postpartum Depression Screening Catch More Cases?

Experts Skeptical of Trump’s So-Called ‘Gold Standard Science’

Single antiviral shot could offer better protection than flu vaccines

‘There’s Something Coming Out of My Body’

FDA Drops REMS Programs for Some CAR-Ts

Categories

Archives